Paper41868151
Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study.
Zhang Y and 6 others. Front Cell Infect Microbiol, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study. Papers, record 41868151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41868151
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ritonavir | Major topic |
| Machine Learning | Major topic |
| Antiviral Agents | Major topic |
| COVID-19 Drug Treatment | Major topic |
| Humans | |
| Drug Monitoring | |
| Female | |
| Retrospective Studies | |
| Male | |
| Middle Aged | |
| SARS-CoV-2 | |
| COVID-19 | |
| Predictive Learning Models | |
| Boosting Machine Learning Algorithms | |
| Aged | |
| Adult |
Source PubMed
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37562225 | Overview of therapeutic drug monitoring and clinical practice. | Talanta | 2024 | https://conductscience.org/library/papers/37562225 | PubMed |
| 2 | 32934000 | Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. | BMJ Evid Based Med | 2021 | https://conductscience.org/library/papers/32934000 | PubMed |
| 3 | 36577095 | VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. | N Engl J Med | 2023 | https://conductscience.org/library/papers/36577095 | PubMed |
| 4 | 35623373 | The future of Paxlovid for COVID-19. | Lancet Respir Med | 2022 | https://conductscience.org/library/papers/35623373 | PubMed |
| 5 | 35617192 | Correction: Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. | PLoS One | 2022 | https://conductscience.org/library/papers/35617192 | PubMed |
| 6 | 35153195 | Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans. | Drug Metab Dispos | 2022 | https://conductscience.org/library/papers/35153195 | PubMed |
| 7 | 37565522 | Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk. | J Infect Dis | 2023 | https://conductscience.org/library/papers/37565522 | PubMed |
| 8 | 36576379 | Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis. | J Med Virol | 2023 | https://conductscience.org/library/papers/36576379 | PubMed |
| 9 | 28255613 | Intensive care medicine research agenda on invasive fungal infection in critically ill patients. | Intensive Care Med | 2017 | https://conductscience.org/library/papers/28255613 | PubMed |
| 10 | 34818379 | Association between voriconazole exposure and Sequential Organ Failure Assessment (SOFA) score in critically ill patients. | PLoS One | 2021 | https://conductscience.org/library/papers/34818379 | PubMed |
| 11 | 37904658 | Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study. | J Korean Med Sci | 2023 | https://conductscience.org/library/papers/37904658 | PubMed |
| 12 | 31640781 | Random forest-based modelling to detect biomarkers for prostate cancer progression. | Clin Epigenetics | 2019 | https://conductscience.org/library/papers/31640781 | PubMed |
| 13 | 36274268 | Simultaneous quantification of nirmatrelvir and ritonavir by LC-MS/MS in patients treated for COVID-19. | J Chromatogr B Analyt Technol Biomed Life Sci | 2022 | https://conductscience.org/library/papers/36274268 | PubMed |
| 14 | 27165788 | Utility of voriconazole therapeutic drug monitoring: a meta-analysis. | J Antimicrob Chemother | 2016 | https://conductscience.org/library/papers/27165788 | PubMed |
| 15 | 37018987 | Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? | Biomed Pharmacother | 2023 | https://conductscience.org/library/papers/37018987 | PubMed |
| 16 | 34914868 | Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. | N Engl J Med | 2022 | https://conductscience.org/library/papers/34914868 | PubMed |
| 17 | 35118917 | Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. | Ann Med | 2022 | https://conductscience.org/library/papers/35118917 | PubMed |
| 18 | 36031408 | Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19). | Clin Infect Dis | 2023 | https://conductscience.org/library/papers/36031408 | PubMed |
| 19 | 35026171 | Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. | Lancet Gastroenterol Hepatol | 2022 | https://conductscience.org/library/papers/35026171 | PubMed |
| 20 | 34048671 | Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis. | J Pharm Pharm Sci | 2021 | https://conductscience.org/library/papers/34048671 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42724114 | Therapeutic drug monitoring of zonisamide in children with epilepsy: development and validation of a precise binary prediction model. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42724114 |
Source PubMed
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CMPK1 | 51727 | PubTator's text mining | https://conductscience.org/library/genes/51727 | NCBI Gene |
| GPT | 2875 | PubTator's text mining | https://conductscience.org/library/genes/2875 | NCBI Gene |
| SLC17A5 | 26503 | PubTator's text mining | https://conductscience.org/library/genes/26503 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41868151
GET https://conductscience.org/api/papers/v1/41868151/references?page=2